Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Aleafia Health Inc ALEAF

Aleafia Health Inc. is a federally licensed Canadian cannabis company offering cannabis products in Canadian adult-use and medical markets and in select international markets. The Company is engaged in the production, sale, and distribution of cannabis. It operates a virtual medical cannabis clinic staffed by physicians and nurse practitioners which provide health and wellness services across... see more

GREY:ALEAF - Post Discussion

Aleafia Health Inc > M&A: AH and CPH for creams and other derma products
View:
Post by stockfy on Jan 29, 2021 3:08am

M&A: AH and CPH for creams and other derma products

AH operates medical cannabis clinics while also producing capsules, oils, sprays and other cannabis stuff for medicinal use, so I think it could make a deal with Cipher Pharmaceuticals (CPH), which has a lot of expertise in many dermatological products.

For instance, CPH produces excellent creams for acne (i.e. its well-known Epuris has 41% market share in Canada), so CPH could make a topical ointment with medicinal cannabis for skin issues too. 

Better yet, I wish AH acquired CPH now because CPH is profitable and dirt-cheap trading just 1.3 times its EBITDA.


And the thing is that CPH has many levers to pull for revenue growth in 2021 because it has many promising drugs in the pipeline with very positive clinical trials to-date.

For instance, CPH's tattoo removal cream seems to be very effective and AH could sell it through its clinics.

What do you think? 
Comment by Nonyah on Jan 29, 2021 7:53am
Aleafia is moving now. CPH is years away from any clinically proven formats. Any IPs the are proven are from Avicanna , currently.
Comment by ImpIications on Jan 29, 2021 9:16am
This post has been removed in accordance with Community Policy
Comment by Nonyah on Jan 29, 2021 9:24am
where are you getting those numbers from. That's bs. I challage you to show me that number is losses
Comment by Toweringmars on Jan 29, 2021 9:52am
Show me where she lost 6.5m a month numb nuts. Again, you don't know how to read financials, or charts for that matter rookie. You should probably rely on Reddit for your stock advice. Hahaha what a rookie.
Comment by stocktracker101 on Jan 29, 2021 10:10am
This post has been removed in accordance with Community Policy
Comment by lmplications on Jan 29, 2021 3:15pm
This post has been removed in accordance with Community Policy
Comment by lmplications on Jan 29, 2021 3:34pm
This post has been removed in accordance with Community Policy
Comment by lmplications on Jan 29, 2021 3:22pm
This post has been removed in accordance with Community Policy
Comment by lmplications on Jan 29, 2021 3:15pm
This post has been removed in accordance with Community Policy
Comment by lmplications on Jan 29, 2021 3:33pm
This post has been removed in accordance with Community Policy
Comment by lmplications on Jan 29, 2021 9:26am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities